کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3975004 1600968 2016 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors
ترجمه فارسی عنوان
مکانیزم های مولکولی برای اثر متقابل بازدارنده های پروتئازوما با درمان پلاتین در تومورهای جامد
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
چکیده انگلیسی

The successful development of the proteasome inhibitor bortezomib as an anticancer drug has improved survival in patients with multiple myeloma. With the emergence of the newly US Food and Drug Administration-approved proteasome inhibitor carfilzomib, ongoing trials are investigating this compound and other proteasome inhibitors either alone or in combination with other chemotherapy drugs. However, in solid tumors, the efficacy of proteasome inhibitors has not lived up to expectations. Results regarding the potential clinical efficacy of bortezomib combined with other agents in the treatment of solid tumors are eagerly awaited. Recent identification of the molecular mechanisms (involving apoptosis and autophagy) by which bortezomib and cisplatin can overcome chemotherapy resistance and sensitize tumor cells to anticancer therapy can provide insights into the development of novel therapeutic strategies for patients with solid malignancies.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Taiwanese Journal of Obstetrics and Gynecology - Volume 55, Issue 1, February 2016, Pages 3–8
نویسندگان
, ,